-
3m 7sPart 2 | Session 9 BMAD Trial: μCor in Ambulatory Decompensated Heart Failure
-
5m 44s
-
8m 2s
-
33m 36sPart 3 | Session 1 ACC.23 Late-breaking Science Wrap Up
-
22m 4sPart 3 | Session 2 What's Hot at ACC.23? Late-breaking Science Preview
-
16m 22s
-
5m 34sPart 4 | Session 2 Lipid Management & the CLEAR Trial with Dr Erin Michos
-
17m 7sPart 4 | Session 3 Obesity Management Strategies in 2023 with Dr Harold Bays
-
15m 9sPart 4 | Session 4 ACC.23 President Interview with Dr B Hadley Wilson
-
1m 17sPart 5 | Session 1 Dr Akowuah: Cardiovascular Research & Message for Early-Career Researchers
-
1m 22sPart 5 | Session 2 Dr Kini: Asking Questions & Her Motivation to Do Research on Plaque
-
5m 29s
-
1m 21sPart 5 | Session 4 Dr Verma: Passion for Electrophysiology & His Advice For Young Researchers
-
3m 33s
-
31sPart 5 | Session 6 Dr Hahn: Innovative Areas of Cardiovascular Science in 2023
-
1m 33sPart 5 | Session 7 Dr Forrest: Structural Heart Innovations and Advice to Young Researchers
-
16m 12sPart 1 | Session 1 The CLEAR-Outcomes Trial with Dr Harriette Van Spall & Dr Steven Nissen
-
16m 24s
-
14m 3s
-
17m 32s
-
12m 7sPart 1 | Session 5 The BIOVASC Trial with Dr Harriette Van Spall & Prof Roberto Diletti
-
5m 59sPart 2 | Session 1 Statins to Protect Heart During Cancer Treatment: The STOP-CA Trial
-
5m 38sPart 2 | Session 2 RENOVATE-COMPLEX-PCI: IVUS Vs OCT Optimisation in Complex PCI
-
8m 1sPart 2 | Session 3 Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study
-
5m 41s
-
3m 46s
-
5m 53s
-
3m 44sPart 2 | Session 7 MK-0616: Oral PCSK9 inhibitor In Hypercholesterolemia Patients
In this short interview from the ACC's 2023 Scientific Sessions, Dr Barry Borlaug (Mayo Clinic, US) joins us virtually to discuss a trial which aims to evaluate the mechanism of benefit for dapagliflozin in patients with heart failure with preserved ejection fraction (Mayo Clinic). The study was conducted over 6 months with 43 patients enrolled in the trial.
The main findings suggest that pulmonary capillary wedge pressure at rest and during exercise was significantly reduced in patients who were treated with dapagliflozin as compared to placebo.
Questions:
- What was the reasoning behind this trial?
- What was the patient population and study design?
- What are your main findings?
- How does this trial contribute to our understanding of the potential benefits of dapagliflozin in patients with HFpEF?
- What are the implications of these findings for clinical practice, and how might they inform future research?
- Why should people be interested in this data?
Recorded remotely from Minnesota, 2023.
Our regular review series View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provides a critical analysis of the late-breaking and featured science results and spotlights impactful data.
For a deeper look into the key clinical trial data revealed at ACC 23, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviews the principal investigators in her regular Late-Breaker Discussion Series.
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research.
More from this programme
Part 1
Late-Breaker Discussion Series
Part 2
Expert Interviews
Part 3
View from the Thoraxcenter
In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC 2023.
Part 4
Comments